We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Open Biosystems' Responds to Sigma-Aldrich and Oxford Biomedica Lawsuit

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Open Biosystems' Responds to Sigma-Aldrich and Oxford Biomedica Lawsuit"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Open Biosystems has responded to the lawsuit filed by Sigma-Aldrich and Oxford Biomedica alleging patent infringement.

Open Biosystems intends to defend these claims and reaffirms its dedication to advancing scientific discoveries through the open distribution of The RNAi Consortium lentiviral libraries.

"These large, publicly traded companies have targeted a privately held and socially responsible company with these accusations," said Troy Moore, chief technology officer, Open Biosystems.

"The claims of patent infringement in the lawsuit are unfounded, and we intend to vigorously defend against them."

"We conduct our business on the highest plane and in a way that results in genomic materials being made available to the research community."

"It is our belief that there is a greater value in making technologies broadly available both to the holder of the intellectual property and to the research community."

Open Biosystems continues to operate under license from the Broad Institute of MIT Harvard, the developers of the TRC lentiviral libraries. Sigma-Aldrich also distributes these libraries.

"It is never our policy to infringe upon intellectual property," said Brian Pollock, CEO of Open Biosystems.

"Open Biosystems' was founded upon an open source business model that supports basic and medical research by making the newest and best life sciences tools readily available to scientists in academia, government and industry."

"This business model is disrupting the strategy of large corporate gate-keepers that are determined to control, not advance, research efforts."